The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

近日，广州医科大学附属第一医院 （国家呼吸医学中心）核医学科王欣璐教授团队与 呼吸疾病国家重点实验室洪城教授团队在核医学顶级期刊《J Nucl Med》（中科院/JCR Q1区，IF=9.1）在线发表了一篇题目为“Targeting ...

Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

DelveInsight's Pulmonary Arterial Hypertension Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 9, 2025 ...